CLINICAL_TRIALS
trial_result
· 2017-10-06
Clinical Trial Update: Topical Use of Difinsa53™ to Prevent Radiation Dermatitis [Phase 1, Phase 2]
Summary
Phase 1 and Phase 2 trials evaluating topical Difinsa53 to prevent radiodermatitis were terminated, with results posted on 2017-10-06.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: ProTechSure Scientific, Inc. | Conditions: Radiodermatitis | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2017-10-06